Αρχική World News Adding Tafasitamab and Lenalidomide to R-CHOP Improves PFS in Patients with Previously... World News Adding Tafasitamab and Lenalidomide to R-CHOP Improves PFS in Patients with Previously Untreated High-Intermediate- or High-Risk DLBCL or HGBL Από Ogkologos - 9 Ιουνίου, 2026 254 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the frontMIND study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Breaking down the new standards for cancer care proposed by NHS... 11 Μαρτίου, 2022 Interpreted cancer awareness workshops: talking about cancer with South-Asian communities 4 Οκτωβρίου, 2022 Worried Cancer Patients Face Delayed Treatment Because Of Pandemic 1 Απριλίου, 2020 FOCUS4: Learning from a landmark clinical trial 25 Απριλίου, 2023 Φόρτωση περισσοτέρων HOT NEWS Encorafenib, Cetuximab Combination Approved for Metastatic Colorectal Cancer Foodie Fridays: Watermelon Salad Selpercatinib Slows Progression of RET-Positive Lung, Medullary Thyroid Cancers Blood test could tailor treatment after surgery
